Physician profile
Robert B Smith
NPI 1821250978
$2,431.16
in general payments reported to CMS, 2019-2025
21 companies · $369 in 2025
The $369 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.93 · 2020: $82.29 · 2021: $765 · 2022: $344 · 2023: $349 · 2024: $461 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,178.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $960.97 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $273.57 | 2021-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $234.14 | 2019-2025 | Entyvio |
| Gilead Sciences, INC. | $201.81 | 2021-2025 | |
| Janssen Biotech, INC. | $151.17 | 2020-2025 | Tremfya |
| Celgene Corporation | $123.84 | 2021-2024 | Zeposia |
| Boston Scientific Corporation | $109.96 | 2024-2025 | Watchman Flx, Resolution 360 Ultra Clip |
| Ardelyx, INC. | $66.47 | 2025 | Ibsrela |
| Genzyme Corporation | $46.52 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $35.38 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $34.90 | 2023 | |
| Madrigal Pharmaceuticals | $33.50 | 2025 | Rezdiffra |
| Nestle Healthcare Nutrition INC. | $30.43 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $26.69 | 2020-2025 | |
| Mallinckrodt Hospital Products INC. | $19.32 | 2023 | Terlivaz |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $16.64 | 2022 | |
| Pfizer INC. | $13.42 | 2024 | |
| Amgen INC. | $13.33 | 2024 | |
| Ucb, INC. | $13.29 | 2019 | |
| Enterra Medical, INC. | $13.27 | 2022 | |
| Ironwood Pharmaceuticals, INC | $12.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.